What is Leerink Partnrs’ Forecast for SAGE Q1 Earnings?

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Sage Therapeutics in a report released on Tuesday, February 11th. Leerink Partnrs analyst M. Goodman anticipates that the biopharmaceutical company will earn ($1.03) per share for the quarter. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.46) per share. Leerink Partnrs also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($0.99) EPS and Q4 2025 earnings at ($0.98) EPS.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%.

A number of other analysts also recently commented on the stock. Oppenheimer decreased their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Wednesday, October 30th. Needham & Company LLC reissued a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday. Canaccord Genuity Group reduced their price objective on Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday. TD Cowen lowered their target price on Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Thursday, November 21st. Finally, Piper Sandler lowered their price objective on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Three analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $9.65.

Sage Therapeutics Price Performance

Shares of SAGE stock opened at $7.16 on Thursday. Sage Therapeutics has a 1-year low of $4.62 and a 1-year high of $27.39. The firm has a market capitalization of $437.98 million, a PE ratio of -1.28 and a beta of 0.94. The business’s fifty day moving average price is $6.34 and its 200 day moving average price is $6.93.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. RTW Investments LP boosted its holdings in shares of Sage Therapeutics by 2.0% during the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock valued at $40,372,000 after acquiring an additional 111,123 shares during the period. State Street Corp lifted its position in Sage Therapeutics by 18.2% in the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock valued at $21,127,000 after purchasing an additional 451,377 shares during the last quarter. Geode Capital Management LLC boosted its stake in Sage Therapeutics by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 1,256,903 shares of the biopharmaceutical company’s stock valued at $6,827,000 after purchasing an additional 14,049 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Sage Therapeutics by 2.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 462,309 shares of the biopharmaceutical company’s stock valued at $2,510,000 after buying an additional 10,116 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Sage Therapeutics by 11.3% during the third quarter. Assenagon Asset Management S.A. now owns 186,039 shares of the biopharmaceutical company’s stock worth $1,343,000 after buying an additional 18,814 shares during the period. 99.22% of the stock is currently owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.